Epidermal growth factor receptor variant III (EGFRvIII) is an extracellular domain mutation of epidermal growth factor receptor (EGFR), which leads to a deletion of exons 2-7 of the EGFR gene and renders the mutant receptor incapable of binding any known ligand. EGFRvIII is considerably expressed in glioblastoma multiforme (GBM), which results in overexpression of the transmembrane tyrosine kinase receptor (EGFR). Therefore, EGFRvIII is related to glioblastoma multiforme (GBM).
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy product with the complete TCR complex without HLA matching dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE